PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
0.31%
ROE near Drug Manufacturers - Specialty & Generic median of 0.31%. Charlie Munger would verify if similar industry forces drive comparable returns.
0.22%
ROA of 0.22% while Drug Manufacturers - Specialty & Generic median is zero. Peter Lynch would see if minimal profitability can widen over time.
0.36%
ROCE of 0.36% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can widen vs. peers.
41.03%
Gross margin 50-75% of Drug Manufacturers - Specialty & Generic median of 56.50%. Guy Spier would question if commodity-like dynamics exist.
6.06%
Margin of 6.06% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if moderate profitability can be leveraged further.
3.96%
Net margin of 3.96% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss would examine if modest profitability can expand.